A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Summary

This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.

Timeline

Start

2026-04-29

Primary completion

2028-08

Completion

2028-12

Drugs

Indications